CARLSBAD, Calif., Nov. 10, 2016 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, today announced that it will present data on the company's first-in-human clinical study in Parkinson's disease at Neuroscience 2016. Session Information Type: Nanosymposium Title: Transplants and Other Treatments of Parkinson's Disease Date: November 14, 2016Time: 8:00 AM Location: SDCC 1B, San Diego Convention Center About the clinical studyThe Phase I clinical study is a dose escalation safety and preliminary efficacy study of ISC-hpNSC®, intracranialy transplanted into patients with moderate to severe Parkinson's disease (ClinicalTrials.gov Identifier: NCT02452723). The open-label, single center, uncontrolled clinical trial will evaluate three different dose regimens of 30,000,000 to 70,000,000 neural cells. A total of 12 participants with moderate to severe Parkinson's disease will be treated. Following transplantation, the patients will be monitored for 12 months at specified intervals, to evaluate the safety and biologic activity of ISC-hpNSC®. PET scan will be performed at baseline, as part of the screening assessment, and at 6 and 12 months after surgical intervention. Clinical responses compared to baseline after the administration of ISC-hpNSC® will be evaluated using various neurological assessments such as Unified Parkinson Disease Rating Scale (UPDRS), Hoehn and Yahr and other rating scales. The study is underway at The Royal Melbourne Hospital in Australia. The study is being overseen by ISCO subsidiary, Cyto Therapeutics Pty Ltd. About Parkinson's diseaseParkinson's disease (PD) is a degenerative disorder of the central nervous system mainly affecting the motor system. The motor symptoms of Parkinson's disease result from the death of dopamine-generating cells in the substantia nigra, a region of the midbrain. Early in the course of the disease, the most obvious symptoms are movement-related; these symptoms include shaking, rigidity, slowness of movement and difficulty with walking and gait. Later, thinking and behavioral problems may arise, with dementia commonly occurring in the advanced stages of the disease, and depression is the most common psychiatric symptom. Parkinson's disease is more common in older people, with most cases occurring after the age of 50.Currently, medications typically used in the treatment of Parkinson's, L-DOPA and dopamine agonists, improve the early symptoms of the disease. As the disease progresses and dopaminergic neurons continue to be lost, the drugs eventually become ineffective while at the same time frequently producing a complication marked by involuntary writhing movements. In 2013 PD resulted in about 103,000 deaths globally, up from 44,000 deaths in 1990.